Nxera Pharma Co., Ltd. (TYO:4565)
Japan · Delayed Price · Currency is JPY | Market Cap | 74.84B -15.6% |
| Revenue (ttm) | 28.70B -2.0% |
| Net Income | -6.14B |
| EPS | -68.17 |
| Shares Out | 90.49M |
| PE Ratio | n/a |
| Forward PE | 18.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 435,800 |
| Average Volume | 683,315 |
| Open | 833.00 |
| Previous Close | 848.00 |
| Day's Range | 815.00 - 840.00 |
| 52-Week Range | 668.00 - 1,048.00 |
| Beta | -0.07 |
| RSI | 49.83 |
| Earnings Date | Feb 13, 2026 |
About Nxera Pharma
Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist i... [Read more]
Financial Performance
In 2024, Nxera Pharma's revenue was 28.84 billion, an increase of 125.87% compared to the previous year's 12.77 billion. Losses were -4.84 billion, -32.74% less than in 2023.
Financial StatementsNews
Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P.
Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P.
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated...
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, ...
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to ex...
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
Tokyo, Japan and Cambridge, UK, 19 November 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that its Board of Directors have decided to replace the current Restricted Share U...
Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism Transcript
Nxera Pharma Co., Ltd. (OTCPK:SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism November 18, 2025 3:00 AM EST Company Participants Hironoshin Nomura - Ex...
Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel
Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, ava...
Nxera Announces Focused Restructuring to Enhance Path to Profitability
Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announced a focused restructuring designed to concentrate investment and...
Nxera Pharma to Host R&D Day 2025
Tokyo, Japan and Cambridge, UK, 4 November 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces that it will hold an R&D Day on 18 Novembe...
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies London Healthcare Conference 2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the...
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
Tokyo, Japan and Cambridge and London, UK, 31 O ctober 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of the ...
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third qua...
Nxera's Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
Tokyo, Japan and Cambridge, UK, 21 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) announces that its partner, Cancer Research UK, presented data from the successfully completed Phas...
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its mult...
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
Tokyo, Japan and Cambridge and London, UK, 17 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) and Cancer Research UK announce that the first patient has been dosed in a Ph...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quar...
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Tokyo, Japan and Cambridge, UK, 6 August 202 5 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategi...
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharma...
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first p...
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Tokyo, Japan and Cambridge, UK, 2 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collabora...
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
Tokyo, Japan and Cambridge, UK, 29 May 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data fro...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ...
Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Pha...
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki w...
Nxera Pharma Announces Appointments to its Executive Leadership Team
Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed...